ANI Pharmaceuticals Expands Ophthalmology Reach As Valuation Signals Upside Potential [Yahoo! Finance]
ANI Pharmaceuticals, Inc. (ANIP)
Last ani pharmaceuticals, inc. earnings: 2/27 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
anipharmaceuticals.com/investors_corporate_profile.php
Company Research
Source: Yahoo! Finance
ANI Pharmaceuticals agreed to acquire Alimera Sciences, adding eye disease treatments Iluvien and Yutiq to its rare disease portfolio. The deal expands ANI Pharmaceuticals' presence in diabetic macular edema and non infectious uveitis, two niche ophthalmic indications. For investors watching NasdaqGM:ANIP, the Alimera acquisition comes with the stock at $74.67 and a 1 year return of 16.2%. Over 3 years, the share price return is 98.5%, and over 5 years it is 128.5%, which indicates that the market has already reacted to previous moves by the company. The addition of Iluvien and Yutiq broadens ANI Pharmaceuticals' rare disease footprint into ophthalmology, giving the company exposure to new specialist prescribers and patient populations. Readers may wish to follow how effectively ANI integrates these assets and develops this new segment, as execution, uptake and any future portfolio decisions could all influence how the story evolves from here. Stay updated on the most importa
Show less
Read more
Impact Snapshot
Event Time:
ANIP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIP alerts
High impacting ANI Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ANIP
News
- 3 Reasons ANIP is Risky and 1 Stock to Buy Instead [Yahoo! Finance]Yahoo! Finance
- Sizing Up ANI Pharmaceuticals (ANIP) After Recent Share Price Pullback [Yahoo! Finance]Yahoo! Finance
- ANI Pharmaceuticals, Inc. (ANIP) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- ANI Pharmaceuticals Targets $1.1B 2026 Revenue as Cortrophin Sales Surge, Gout Launch Set for Midyear [Yahoo! Finance]Yahoo! Finance
- Insider Trades And Rare Disease Growth Shape ANI Pharmaceuticals Valuation [Yahoo! Finance]Yahoo! Finance
ANIP
Earnings
- 2/27/26 - Beat
ANIP
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- ANIP's page on the SEC website